Trial Profile
A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2023
Price :
$35
*
At a glance
- Drugs Sodium thiosulfate (Primary)
- Indications Sensorineural hearing loss
- Focus Registrational; Therapeutic Use
- Sponsors Fennec Pharmaceuticals
- 06 Jun 2023 According to a Fennec Pharmaceuticals media release, the company received marketing authorization by the European Commission for Pedmarqsi (sodium thiosulfate) in pediatric patients with localized, non-metastatic solid tumors, based on SIOPEL 6 and Clinical Oncology Group [COG] Protocol ACCL0431). The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
- 31 Mar 2023 According to a Fennec Pharmaceuticals media release, ratification of the CHMP recommendation is expected by early June 2023
- 31 Mar 2023 According to a Fennec Pharmaceuticals media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion and recommended granting a Marketing Authorization for Pedmarqsi for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localized, non-metastatic, solid tumors, based on SIOPEL 6 and Clinical Oncology Group [COG] Protocol ACCL0431.